Buffett Apprentice
Steady Voyager
$藥明康德.HK 發盈喜，料 2022 年全年營業收入按年增 71.8% 至 393.5 億元人民幣（人民幣，下同）；淨利潤按年增 72.9% 至 88.1 億元，即每股收益約 3.01 元；扣除非經常性損益淨利潤則增 1 倍至 82.6 億元，經調整淨利潤按年增 83.2% 至約 94 億元。
藥明康德指出，期內業務增長歸因合同研究、開發與生產模式（CRDMO）及合同測試、研發與生產模式（CTDMO）持續驅動集團發展。
另外，集團去年資本投資標的產生及衍生金融工具部分產生的公允價值變動和投資損益，上述淨收益各按年減少 89% 至 1.8 億元及 1.1 億元。
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Like
